By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

Popular weight-loss drugs are meant to be lifelong medications treating a disease, not lifestyle fixes.

Novo Nordisk (NVO) stock is in focus as the company's advertising expenditure for its GLP-1s, Wegovy and Ozempic, exceeds that for Lilly's (LLY) rivals. Read more here.

The 23-time Grand Slam champion tells PEOPLE that she feels better than ever since dropping 34 lbs. with a GLP-1 ...

By Amina Niasse NEW YORK, Jan 28 (Reuters) - Telehealth company Ro has had an influx of new customers seeking the newly ...

Serena Williams has appeared in several Super Bowl commercials, but never one quite like this. In a new spot from ...

Ro is making its Super Bowl debut, enlisting Williams to challenge misconceptions about GLP-1 use.

As layoffs pile up, workers are feeling increasingly anxious about the job market. Economists have said businesses are in a "no-hire, no-fire" standstill as hiring stalls overall. But a growing ...

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

Novo Nordisk spent nearly $500 million on advertising GLP-1 drugs Wegovy and Ozempic in the U.S. through 2025, targeting ...

GLP-1 medications, such as Ozempic and Wegovy, have gained significant attention for their effectiveness in weight management. However, Ro's campaign seeks to address the stigma attached to these ...